CERC 501

Drug Profile

CERC 501

Alternative Names: CERC501; LY 2456302

Latest Information Update: 08 May 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Cerecor
  • Class
  • Mechanism of Action Opioid kappa receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder; Smoking withdrawal
  • Phase I Alcoholism

Most Recent Events

  • 01 May 2017 Efficacy data from the phase II RAPID KOR trial in Major depressive disorder released by Cerecor
  • 05 Dec 2016 Top-line adverse events data from a phase II trial in Smoking withdrawal released by Cerecor
  • 01 Dec 2016 Cerecor Inc completes a phase II trial in Smoking withdrawal in USA (NCT02641028)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top